Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 11/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25343010 | 0.95 | KCNJ1 (0.57) | KCNJ1KCNH2ABCB1ABCG2HRH3 | |
| SCHEMBL7598211 | 0.84 | ABCB1 (0.74) | KCNJ1KCNH2ABCB1ABCG2HRH3 | |
| SCHEMBL30643086 | 0.81 | ABCB1 (0.51) | ABCB1ABCG2HRH3SIGMAR1 | |
| SCHEMBL24348790 | 0.81 | ABCB1 (0.51) | ABCB1ABCG2HRH3SIGMAR1 | |
| SCHEMBL24349919 | 0.78 | ABCB1 (0.51) | KCNJ1KCNH2ABCB1ABCG2HRH3 | |
| Water SCHEMBL10361432 | 0.76 | KCNJ1 (0.68) | KCNJ1KCNH2ABCB1ABCG2HRH3 | |
| SCHEMBL30643082 | 0.76 | ABCB1 (0.51) | ABCB1ABCG2HRH3SIGMAR1 | |
| SCHEMBL24348772 | 0.76 | ABCB1 (0.51) | ABCB1ABCG2HRH3SIGMAR1 | |
| Water SCHEMBL10361433 | 0.76 | KCNJ1 (0.68) | KCNJ1KCNH2ABCB1ABCG2HRH3 | |
| SCHEMBL15238463 | 0.76 | MEN1 (0.68) | HRH3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| US-20220106312-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106312-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, CYP3A5, CYP3A7 | KCNJ1 1336/4885KCNH2 2416/4885ABCB1 1/4885 |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, ABCC1, UGT2B7 | KCNJ1 2343/4885KCNH2 2583/4885ABCB1 1/4885 |
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ABCB1, CYP3A5, CYP3A7 | KCNJ1 1336/4885KCNH2 2416/4885ABCB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.